Let’s blame the drug companies for high drug prices!

  • The total impact of obesity and its related complications on the United States’ economic output has been estimated at between 4 and 8 percent of gross domestic product.
  • According to the American Diabetes Association, the annual cost of diabetes in 2017 was $327 billion, including $237 billion in direct medical expenditures and $90 billion in reduced worker productivity.
  • The effects of poor diet and inadequate physical activity at any weight — contributed to declines in life expectancy in 2015 and 2016.
  • The obesity epidemic is largely overlooked as the media continue to blame drug companies and PBM’s for high drug costs.

Continue reading

Dr. Baselga and a serious lack of judgement

  • One of the world’s top breast cancer doctors failed to disclose millions of dollars in payments from drug and health care companies in recent years, omitting his financial ties from dozens of research articles in prestigious publications like The New England Journal of Medicine and The Lancet.
  •  Did not follow financial disclosure rules set by the American Association for Cancer Research when he was president of the group.
  • The feedback from within the medical community has been sharp “Dr. José Baselga’s demonstrated lack of ethics by not disclosing his ties to big pharma is a cancerous lesion on the entire medical research community. SHAME, SHAME, Dr. Baselga”.

Continue reading

Most dangerous prescription drugs not opioids

  • 48.8%, nearly half of anticoagulant adverse events required a hospital stay.
  • Based on CDC data there were nearly 22,000 severe injuries, including more than 3,000 deaths, reported by patients and health care workers relating to blood thinners in 2016.
  • The annual number of people harmed by anticoagulants could be as much as ten times greater than voluntary reports indicate, reaching nearly a quarter of a million people.
  • As many as one-quarter of people with atrial fibrillation who have a low risk of stroke are given blood-thinning drugs they likely don’t need.

Continue reading

Gilead exec’s flee after milking the health care system

  • Executives at Gilead are leaving a sinking ship.
  • Sales of a breakthrough drug they purchased through the acquisition of Kite Pharma  have failed to match expectations.
  • Gilead charges thousands of dollars for a drug for their AIDS drug, but competition is creeping in.
  • Since Truvada was approved for HIV prevention six years ago, its average wholesale price has increased by about 45 percent.
  • Without more drugs to buy Gilead’s stock has been declining.

Continue reading

Change is coming to drug pricing, whether it’s painful or not

  • Some pharma companies have seemingly defied the emphasis on drug costs by raising drug prices.
  • Change is coming to prescription drug pricing, whether it’s painful or not for pharmaceutical companies,” Health and Human Services (HHS) Secretary Alex Azar said in a speech Monday at a health policy conference.
  • “The drug companies that recently increased prices will be remembered for creating a tipping point in U.S. drug pricing policy,” Azar said.
  • Drug prices were raised because Wall Street is their primary customer, not patients.

Continue reading

Pharma refuses to acknowledge that a storm is coming

KEY TAKEAWAY: Large majorities of Republican, Democratic and independent voters say they would be more likely to vote for candidates in this year’s midterm elections who are committed to bringing down the cost of prescription drugs according to a poll released last week by the Kaiser Family Foundation (KFF).  Yet companies like AbbVie raised prices of drugs and are blocking generic versions of their medications.  Change is coming, but too many pharma CEO’s are still too subservient to Wall Street.  Continue reading